InfiNano: Democratizing Cancer Care through Gold-Nanoliposome Photothermal Therapy

Transformative Nanotechnology Pivot

InfiNano began as Piscium Health Sciences, pioneering the world’s first nano-diamond dental burs. Building on this foundation, it has now transformed its focus toward cancer therapeutics, emphasizing affordability, safety, and clinical efficacy. The company’s broader vision includes innovating nanotechnology-based therapies targeted at major noncommunicable diseases, such as cancer, wound and trauma healing, and advanced drug delivery systems, aiming to significantly improve patient outcomes across these areas.

Flagship Innovation: AuLipos PTT

The core of InfiNano’s innovation is AuLipos PTT, which combines gold nanoparticles encapsulated in liposomes and coated with tumor-homing peptides. When activated by near-infrared light, this photothermal therapy generates precise, localized heat that destroys tumor cells while safeguarding adjacent healthy tissue. Preclinical studies report encouraging outcomes, including nearly double the life expectancy in late-stage oral cancer models, zero residual toxicity, and the feasibility of a single-dose or minimal-session treatment protocol; potentially revolutionizing patient experience and adherence.

Unmet Need and Market Opportunity

In India, conventional cancer therapies are costly; averaging around INR 400,000 per patient; and are predominantly available only in urban centers, leaving rural populations underserved. With India accounting for over one-third of global oral cancer cases and 63% of patients facing catastrophic out-of-pocket expenses, the need for affordable and accessible treatment options is urgent. InfiNano strategically targets the underserved $300–400 million Indian oral cancer market and is poised to benefit from the expanding global nanotechnology oncology market projected to grow from $3.2 billion in 2024 to $9.4 billion by 2033, with a strong 12.8% CAGR.

Rural Accessibility and Affordability

By reducing therapy costs dramatically to INR 10,000 and optimizing the procedure for delivery through primary health centers, InfiNano enables treatment administration by paramedics within existing rural healthcare frameworks. This approach effectively bridges the rural-urban healthcare divide, providing critical access to advanced cancer therapy for approximately 70% of India’s population living outside urban centers. The company’s model also integrates with the Ayush Bharat health scheme, enhancing affordability and wide-scale reach.

Clinical Validation and Partnerships

InfiNano has established key collaborations with prestigious cancer research institutions, including Tata Memorial Centre and ACTREC, to conduct GLP-compliant preclinical studies, GMP manufacturing, and ongoing clinical trials. These partnerships strengthen the company’s clinical validation process and facilitate regulatory approval, fast-tracking commercialization efforts aimed at accelerated market entry.

Leadership and Future Expansion

Guided by visionary leadership; serial entrepreneur Pradyumn Singh and esteemed scientists Dr. Rohit Srivastava and Dr. Abhijit De; InfiNano is well-positioned for rapid growth. The company’s technology platform is designed for expansion beyond oral cancer, with plans to develop nanodrug delivery solutions for wound healing, immunotherapy enhancement, skincare applications, and nanoparticle active pharmaceutical ingredient production. This diversified pipeline reinforces InfiNano’s trajectory to become a global leader in affordable, patient-focused nanomedicine solutions.